Reported Earlier, Adlai Nortye To Present Encouraging Data Of The Combination Of AN0025 And Definitive Chemoradiotherapy (dCRT) At ASCO 2024

5/24/24 1:42:01 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ANL alert in real time by email

Adlai Nortye a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Get the next $ANL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANL

Date	Price Target	Rating	Analyst
9/4/2024	$9.00	Buy	H.C. Wainwright
10/24/2023	$30.00	Overweight	Cantor Fitzgerald

More analyst ratings

$ANL
Press Releases

Fastest customizable press release news feed in the world

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom
8/8/24 8:00:00 AM ET
$ANL
Biotechnology: Pharmaceutical Preparations
Health Care
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024. AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrop
5/23/24 9:03:04 PM ET
$ANL
Biotechnology: Pharmaceutical Preparations
Health Care
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 ("EP4") antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT') ("CRT") for the treatment of rectal cancer. The study has been developed and is
5/22/24 8:00:00 AM ET
$ANL
Biotechnology: Pharmaceutical Preparations
Health Care

$ANL
Market Insights

Live Market Insights

Cantor Fitzgerald Reiterates Overweight on Adlai Nortye
Cantor Fitzgerald analyst Louise Chen reiterates Adlai Nortye (NASDAQ:ANL) with a Overweight.
6/20/24 1:22:44 PM ET
$ANL
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNCY) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. Venus Concept (NASDAQ:VERO) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. Gossamer Bio (NASDAQ:GOSS) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. Poseida Therapeuti
6/11/24 4:31:35 PM ET
$AMIX
$ANL
$BSGM
$CAPR
Medical/Dental Instruments
Health Care
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Venus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. Adlai Nortye (NASDAQ:ANL) shares moved upwards by 56.64% to $6.72. The market value of their outstanding shares is at $247.9 million. BioCardia (NASDAQ:BCDA) shares moved upwards by 52.57% to $6.66. The market value of their outstanding shares is at $12.1 million. Geron (NASDAQ:GERN) stock rose 22.36% to $4.76. The market value of their outstanding shares is at $2.8 billion. Seelos Therapeutics (NASDAQ:SEEL) stock moved upwards by 14.66% to $1.29. The market value of their outstanding shares is at $3.3 million. Inda
6/7/24 8:08:00 AM ET
$ANL
$BCDA
$BMEA
$GERN
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments

Reported Earlier, Adlai Nortye To Present Encouraging Data Of The Combination Of AN0025 And Definitive Chemoradiotherapy (dCRT) At ASCO 2024

Chat with this insight

Recent Analyst Ratings for
$ANL

$ANL
SEC Filings

SEC Form 6-K filed by Adlai Nortye Ltd.

SEC Form 6-K filed by Adlai Nortye Ltd.

SEC Form 6-K filed by Adlai Nortye Ltd.

$ANL
Press Releases

Fastest customizable press release news feed in the world

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

$ANL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Adlai Nortye Ltd.

$ANL
Leadership Updates

Live Leadership Updates

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

$ANL
Market Insights

Live Market Insights

Cantor Fitzgerald Reiterates Overweight on Adlai Nortye

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

$ANL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Adlai Nortye Ltd. with a new price target

Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. with a new price target

Reported Earlier, Adlai Nortye To Present Encouraging Data Of The Combination Of AN0025 And Definitive Chemoradiotherapy (dCRT) At ASCO 2024

Chat with this insight

Recent Analyst Ratings for $ANL

$ANL SEC Filings

SEC Form 6-K filed by Adlai Nortye Ltd.

SEC Form 6-K filed by Adlai Nortye Ltd.

SEC Form 6-K filed by Adlai Nortye Ltd.

$ANL Press Releases

Fastest customizable press release news feed in the world

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

$ANL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Adlai Nortye Ltd.

$ANL Leadership Updates

Live Leadership Updates

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

$ANL Market Insights

Live Market Insights

Cantor Fitzgerald Reiterates Overweight on Adlai Nortye

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

$ANL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Adlai Nortye Ltd. with a new price target

Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. with a new price target

Recent Analyst Ratings for
$ANL

$ANL
SEC Filings

$ANL
Press Releases

$ANL
Large Ownership Changes

$ANL
Leadership Updates

$ANL
Market Insights

$ANL
Analyst Ratings